Oxidative status of platelets in normal and thalassemic blood

Summary

Chronic platelet activation may be involved in thromboembolic complications, a leading cause of morbidity and mortality in β-thalassemia. Oxidative stress, with the generation of reactive oxygen species (ROS), is suspected to play a role in the pathophysiology of thalassemia and cardiovascular disorders. In the present study, we adapted flow cytometric techniques to measure oxidative state markers, ROS generation and reduced glutathione (GSH) content in platelets. Our results show that platelets obtained from β-thalassemic patients contain higher ROS and lower GSH levels than do platelets from normal donors, indicating a state of oxidative stress. In the absence of any known inherent abnormality in thalassemia platelets, this may be attributed to continuous exposure to oxidative insults from extra-platelet sources. We found that exposure of platelets to oxidants such as hydrogen peroxide and tertbutylhydroperoxide or to the platelet activators thrombin, calcium ionophore or phorbol myristate acetate stimulated the platelets’ oxidative stress.This was also increased by plasma of thalassemia patients, and decreased following treatment of the plasma with the iron-chelator Desferoxamin. Iron and hemin, the levels of which are augmented in plasma of thalassemia patients, stimulated the platelets’ oxidative stress.The oxidative status of the platelets was also affected by red blood cells (RBC); it was higher in normal platelets incubated with thalassemic RBC than with normal RBC. Normal RBC stimulated with hydrogen peroxide had a greater effect on platelets than did unstimulated RBC.The platelets’ oxidative stress was ameliorated by antioxidants such as N-acetyl-L-cysteine and vitamin C. Our findings indicate that in thalassemia, platelets undergo a state of oxidative stress, leading to their activation and potentially to thromboembolic consequences, and suggest that this hypercoagulable state might be treated with antioxidants.

Keywords

Thalassemia - platelets - free radicals - glutathione - flow cytometry

• References

• 1 Eldor A, Rachmilewitz EA. The hypercoagulable state in thalassemia. Blood 2002; 99: 36-43.
• 2 Eldor A. Abnormal platelet functions in beta thalassaemia. Scand J Haematol 1978; 20: 447-52.
• 3 Hussain MA, Hutton RA, Pavlidou O. et al. Platelet function in beta-thalassaemia major. J Clin Pathol 1979; 32: 429-33.
• 4 Rinder HM, Snyder EL, Bonan JL. et al. Activation in stored platelet concentrates: correlation between membrane expression of P-selectin, glycoprotein IIb/IIIa, and betathromboglobulin release. Transfusion 1993; 33: 25-29.
• 5 Pasin M, Yavuzer S, Tekin M. et al. Oxygen free radical-dependent increased platelet function in beta-thalassemia major patients. Thromb Res 1998; 92: 283-6.
• 6 Bergendi L, Benes L, Durackova Z. et al. Chemistry, physiology and pathology of free radicals. Life Sci 1999; 65: 1865-74.
• 7 Blockmans D, Deckmyn H, Vermylen J. Platelet activation. Blood Rev 1995; 09: 143-56.
• 8 Iuliano L, Colavita AR, Leo R. et al. Oxygen free radicals and platelet activation. Free Radic Biol Med 1997; 22: 999-1006.
• 9 Hanson SR, Harker LA. Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-Larginyl chloromethyl ketone. Proc Natl Acad Sci U S A 1988; 85: 3184-8.
• 10 Eidt JF, Allison P, Noble S. et al. Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury. J Clin Invest 1989; 84: 18-27.
• 11 Kelly AB, Marzec UM, Krupski W. et al. Hirudin interruption of heparin-resistant arterial thrombus formation in baboons. Blood 1991; 77: 1006-12.
• 12 Kohen R, Nyska A. Oxidation of biological systems: oxidative stress phenomena, antioxidants, redox reactions, and methods for their quantification. Toxicol Pathol 2002; 30: 620-50.
• 13 Hedley DW, Chow S. Evaluation of methods for measuring cellular glutathione content using flow cytometry. Cytometry 1994; 15: 349-58.
• 14 de Zwart LL, Meerman JH, Commandeur JN. et al. Biomarkers of free radical damage applications in experimental animals and in humans. Free Radic Biol Med 1999; 26: 202-26.
• 15 Droge W. Free radicals in the physiological control of cell function. Physiol Rev 2002; 82: 47-95.
• 16 O’Connor JE, Kimler BF, Morgan MC. et al. A flow cytometric assay for intracellular nonprotein thiols using mercury orange. Cytometry 1988; 09: 529-32.
• 17 Clark RA, Klebanoff SJ. Neutrophil-platelet interaction mediated by myeloperoxidase and hydrogen peroxide. J Immunol 1980; 124: 399-405.
• 18 Plummer JL, Smith BR, Sies H. et al. Chemical depletion of glutathione in vivo. Methods Enzymol 1981; 77: 50-59.
• 19 Amer J, Goldfarb A, Fibach E. Flow cytometric measurement of reactive oxygen species production by normal and thalassaemic red blood cells. Eur J Haematol 2003; 70: 84-90.
• 20 Sanner BM, Meder U, Zidek W. et al. Effects of glucocorticoids on generation of reactive oxygen species in platelets. Steroids 2002; 67: 715-9.
• 21 Seno T, Inoue N, Gao D. et al. Involvement of NADH/NADPH oxidase in human platelet ROS production. Thromb Res 2001; 103: 399-409.
• 22 Amer J, Goldfarb A, Fibach E. Flow cytometric analysis of the oxidative status of normal and thalassemic red blood cells. Cytometry 2004; 60A (01) 73-80.
• 23 Bass DA, Parce JW, Dechatelet LR. et al. Flow cytometric studies of oxidative product formation by neutrophils: a graded response to membrane stimulation. J Immunol 1983; 130: 1910-17.
• 24 Emmendroffer A, Hecht M, Lohmann-Matthes ML, Rocesler J. Fast and easy method to determine the production of reactive oxygen intermediates by human and murine phagocytes using dihydrorhodamine 123. J Immunol Methods 1990; 131: 269-75.
• 25 Olas B, Wachowics B, Bald E. et al. The protective effects of resveratrol against changes in blood platelet thiols induced by platinum compounds. J. Physiol Pharmacol 2004; 55: 467-76.
• 26 Caccese D, Pratico D, Ghiselli A. et al. Superoxide anion and hydroxyl radical release by collagen-induced platelet aggregation - role of arachidonic acid metabolism. Thromb Haemost 2000; 83: 485-90.
• 27 Levine PH, Weinger RS, Simon J. et al. Leukocyte-platelet interaction. Release of hydrogen peroxide by granulocytes as a modulator of platelet reactions. J Clin Invest 1976; 57: 955-63.
• 28 Iuliano L, Violi F, Pedersen JZ. et al. Free radical-mediated platelet activation by hemoglobin released from red blood cells. Arch Biochem Biophys 1992; 299: 220-4.
• 29 Pratico D, Iuliano L, Pulcinelli FM. et al. Hydrogen peroxide triggers activation of human platelets selectively exposed to nonaggregating concentrations of arachidonic acid and collagen. J Lab Clin Med 1992; 119: 364-70.
• 30 Malle E, Ibovnik A, Stienmetz A. et al. Identification of glycoprotein IIb as the lipoprotein(a)-binding protein on platelets. Lipoprotein(a) binding is independent of an arginyl-glycyl-aspartate tripeptide located in apolipoprotein(a). Arterioscler Thromb 1994; 14: 345-52.
• 31 Solum NO. Procoagulant expression in platelets and defects leading to clinical disorders. Arterioscler Thromb Vasc Biol 1999; 19: 2841-6.
• 32 Salvemini D, de Nucci G, Sneddon JM. et al. Superoxide anions enhance platelet adhesion and aggregation. Br J Pharmacol 1989; 97: 1145-50.
• 33 Olas B, Wachowicz B. Resveratrol and vitamin C as antioxidants in blood platelets. Thromb Res 2002; 106: 143-8.
• 34 Wilkinson IB, Megson IL, MacCallum H. et al. Oral vitamin C reduces arterial stiffness and platelet aggregation in humans. J Cardiovasc Pharmacol 1999; 34: 690-3.
• 35 Labinjoh C, Newby DE, Wilkinson IB. et al. Effects of acute methionine loading and vitamin C on endogenous fibrinolysis, endothelium-dependent vasomotion and platelet aggregation. Clin Sci 2001; 100: 127-35.
• 36 Olas B, Wachowicz B, Buczynski A. Vitamin C suppresses the cisplatin toxicity on blood platelets. Anticancer Drugs 2000; 11: 487-93.